Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
MAP4K1
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "MAP4K1" in MCE Product Catalog:
Target:
Research Areas:
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs) .
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .
Target:
PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)
Research Areas:
DB1113 is a multi-kinase PROTAC degrader. DB1113 induces the ubiquitination and degradation of ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used to study diseases or disorders mediated by aberrant kinase activity .
Target:
PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK NEKs
Research Areas:
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .
Cat. No.: HY-RS08071
Target:
Research Areas:
MAP4K1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP4K1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08072
Target:
Research Areas:
Map4k1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map4k1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08073
Target:
Research Areas:
Map4k1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Map4k1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-170443
CAS No.: 2736458-30-1
PF-07265028 is a selective hematopoietic progenitor kinase 1 (HPK1/MAP4K1). PF-07265028 can be used in the research of cancer. PF-07265028 shows very potent cellular activity as measured by pSLP76 IC50 (17 nM) .
Cat. No.: HY-156509
CAS No.: 2578802-72-7
HPK1-IN-38 (compound 15) is a MAP4K1/HPK1 inhibitor，can be used for HPK1 related disorders research .
Cat. No.: HY-143868
CAS No.: 2268794-52-9
HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .
Cat. No.: HY-143871
CAS No.: 2700292-56-2
HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .
Cat. No.: HY-162544
CAS No.: 2893885-31-7
PROTAC HPK1 Degrader-2 (compound 3) is a PROTAC degrader targeting hematopoietic progenitor kinase MAP4K1/HPK1, with a DC50 of 23 nM in human PBMCs. PROTAC HPK1 Degrader-2 is applicable for cancer research .
Cat. No.: HY-P706070
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: MAP4K1; MEK Kinase Kinase 1; Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1; MEKKK 1; HPK1; Mitogen-Activated Protein Kinase Kinase Kinase Kinase; Hematopoietic Progenitor Kinase 1; Non-Specific Serine/Threonine Protein Kinase; MAPK/ERK Kinase Ki
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-187930
CAS No.: 2965385-11-7
HPK1-IN-72 is an orally active and selective HPK1/MAP4K1 inhibitor with an IC50 of 52.4 nM against human targets. HPK1-IN-72 inhibits HPK1 activation, blocks the negative regulation of T cell receptor signaling, restores T cell receptor signal transduction and enhances T cell function. HPK1-IN-72 suppresses tumor growth, exhibits potent single-agent anti-tumor efficacy, and also produces synergistic effects with anti-PD-1 antibodies or anti-PD-L1/IL-15 immunocytokine prodrugs. HPK1-IN-72 can be used in research related to breast cancer, colorectal cancer and prostate cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
